glp 1 arthritis pain Can Ozempic, Monjaro & GLP-1 Drugs REVERSE Arthritis?! GLP-1 Receptor Agonists May Improve

In the past seven years, the proportion of new, commercial patients who are rejected for a launch brand increased from 37% to 56%, such that more than half of the attempts to initiate a new treatment in 2022 were unfilled the first year

Canada approves a generic alternative to Ozempic and Wegovy

This altered revenue composition has clearly indicated that share of insulin would continue to shrink not only in Novos topline in future but also in the overall pie of the diabetes market around the globe

Here's who is (and is not) an ideal candidate for medical weight loss:

Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.